GDBspace, a Space Pharmaceuticals company, selected among 10 Swiss scale-up companies to join the Venture Kick Scale Up Bootcamp

GDBspace, a Space Pharmaceuticals company specialized in computational methods for drug discovery, was selected by the Venture Kick jury, to join the Venture Kick Scale Up Bootcamp among 10 Swiss scale-up companies.

The Swiss companies selected are: Lino Biotech, Galventa, Alithea Genomics, Resistell, Oncobit, Healiva, GDBspace, FluoSphera, Recolony and Alithea Genomics.

Dr. Jingwen Shi, CBO at Space Pharmaceuticals said “We are really glad to be part of the Venture Kick Scale Up Bootcamp! This is a very good platform to connect with large corporates for business development, and everyone from large corporates was very curious and eager to discuss at this exclusive bootcamp”.

Space Pharmaceuticals appoints Dr. Kapila Gunasekera as Senior Computational Chemist

We are pleased to welcome Dr. Kapila Gunasekera as Senior Computational Chemist. Dr. Gunasekera is a molecular biology and computational biology scientist with experience spanning from biology to genetics, bioinformatics and peptide chemistry, as well as a track records of excellent publications. At GDBspace, Dr. Kapila Gunasekera will work on computational peptide design.

Space Pharmaceuticals appoints Dr. Simon Nebel as Business advisor

Space Pharmaceuticals is pleased to welcome Dr. Simon Nebel as Business Advisor.

Dr. Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions for Aravis portfolio companies. He has been the board member or observer in fourteen companies. Before joining Aravis, he was a group strategist at UBS. Dr. Nebel got his PhD in Biophysics at the Biocentre of the University of Basel and an MBA from the London Business School.

Space Pharmaceuticals appoints Prof. Hans-Joachim Böhm as Scientific advisor

Space Pharmaceuticals is pleased to welcome Prof. Hans-Joachim Böhm as Scientific advisor.

Prof. Hans-Joachim Böhm is a professor of Bioinformatics at the University of Basel, working on the development of new methods for computer-aided drug design, as well as a member of the Swiss Science Council. He worked for several years at Roche in both Basel and Palo Alto (USA) where he became global head of chemical research. He also worked at Siemens in Munich in the field of microelectronics research and then at BASF in Ludwigshafen in structure-based design of drugs. Prof. Böhm studied chemistry at the University of Karlsruhe where he did both his PhD and his Post Doc.